Opus Point Partners Management LLC lessened its stake in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 35.7% during the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 2,622 shares of the biopharmaceutical company’s stock after selling 1,454 shares during the quarter. Regeneron Pharmaceuticals makes up 1.8% of Opus Point Partners Management LLC’s holdings, making the stock its 18th biggest holding. Opus Point Partners Management LLC’s holdings in Regeneron Pharmaceuticals were worth $903,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Ostrum Asset Management bought a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth $108,000. Pin Oak Investment Advisors Inc. bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth $152,000. Advisory Services Network LLC grew its stake in shares of Regeneron Pharmaceuticals by 147.0% during the fourth quarter. Advisory Services Network LLC now owns 447 shares of the biopharmaceutical company’s stock worth $168,000 after buying an additional 266 shares during the last quarter. Mackenzie Financial Corp bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth $204,000. Finally, 180 Wealth Advisors LLC bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth $211,000. 66.22% of the stock is currently owned by hedge funds and other institutional investors.
In other news, Director George L. Sing sold 7,000 shares of the company’s stock in a transaction dated Wednesday, May 9th. The shares were sold at an average price of $285.29, for a total transaction of $1,997,030.00. Following the transaction, the director now owns 127,772 shares in the company, valued at $36,452,073.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Chairman P Roy Vagelos sold 74,710 shares of the company’s stock in a transaction dated Thursday, June 21st. The shares were sold at an average price of $327.87, for a total transaction of $24,495,167.70. Following the transaction, the chairman now owns 553,121 shares in the company, valued at approximately $181,351,782.27. The disclosure for this sale can be found here. In the last 90 days, insiders sold 214,718 shares of company stock worth $67,470,695. 12.42% of the stock is owned by company insiders.
REGN has been the topic of a number of research reports. UBS Group cut shares of Regeneron Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Monday, April 9th. Raymond James reaffirmed a “market perform” rating on shares of Regeneron Pharmaceuticals in a research note on Monday, April 9th. They noted that the move was a valuation call. Zacks Investment Research cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, April 11th. BidaskClub cut shares of Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, April 18th. Finally, Credit Suisse Group cut their price target on shares of Regeneron Pharmaceuticals from $440.00 to $420.00 and set a “buy” rating on the stock in a report on Tuesday, April 17th. Three investment analysts have rated the stock with a sell rating, fourteen have issued a hold rating and ten have issued a buy rating to the company’s stock. Regeneron Pharmaceuticals currently has an average rating of “Hold” and an average target price of $420.68.
Regeneron Pharmaceuticals opened at $344.99 on Friday, MarketBeat reports. The firm has a market capitalization of $36.81 billion, a P/E ratio of 21.85, a PEG ratio of 1.23 and a beta of 1.40. The company has a current ratio of 3.59, a quick ratio of 2.94 and a debt-to-equity ratio of 0.11. Regeneron Pharmaceuticals Inc has a 12-month low of $281.89 and a 12-month high of $526.12.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, May 3rd. The biopharmaceutical company reported $4.67 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.08 by ($0.41). The firm had revenue of $1.51 billion during the quarter, compared to analyst estimates of $1.50 billion. Regeneron Pharmaceuticals had a net margin of 23.54% and a return on equity of 29.92%. Regeneron Pharmaceuticals’s quarterly revenue was up 14.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.92 EPS. equities analysts anticipate that Regeneron Pharmaceuticals Inc will post 17.2 earnings per share for the current fiscal year.
Regeneron Pharmaceuticals Profile
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.